UY30637A1 - Polimorfo b de n-{2-fluoro-5-[3-(tiofen-2-carbonil)-pirazolo[1,5-a]pirimidin-7-il]-fenil}-n-metil-acetamida - Google Patents

Polimorfo b de n-{2-fluoro-5-[3-(tiofen-2-carbonil)-pirazolo[1,5-a]pirimidin-7-il]-fenil}-n-metil-acetamida

Info

Publication number
UY30637A1
UY30637A1 UY30637A UY30637A UY30637A1 UY 30637 A1 UY30637 A1 UY 30637A1 UY 30637 A UY30637 A UY 30637A UY 30637 A UY30637 A UY 30637A UY 30637 A1 UY30637 A1 UY 30637A1
Authority
UY
Uruguay
Prior art keywords
pyrimidin
fluoro
carbonyl
methyl
thiofen
Prior art date
Application number
UY30637A
Other languages
English (en)
Inventor
Antonio Guglietta
Palomer Albert
Anglada Luis
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37789824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30637(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of UY30637A1 publication Critical patent/UY30637A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a un nuevo polimorfo de N-{2-fluoro-5-[3-(tiofen-2-carbonil)-pirazolo[1,5-a]pirimidin-7-il]-fenil}-N-metil-acetamida,a procedimientos para su preparacion, a su uso como medicamento, su uso en la fabricacion de un medicamento y a composiciones farmacéuticas que comprenden un nuevo polimorfo.
UY30637A 2006-10-11 2007-10-10 Polimorfo b de n-{2-fluoro-5-[3-(tiofen-2-carbonil)-pirazolo[1,5-a]pirimidin-7-il]-fenil}-n-metil-acetamida UY30637A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06122138A EP1918290A1 (en) 2006-10-11 2006-10-11 Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-N-methyl-acetamide

Publications (1)

Publication Number Publication Date
UY30637A1 true UY30637A1 (es) 2008-05-02

Family

ID=37789824

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30637A UY30637A1 (es) 2006-10-11 2007-10-10 Polimorfo b de n-{2-fluoro-5-[3-(tiofen-2-carbonil)-pirazolo[1,5-a]pirimidin-7-il]-fenil}-n-metil-acetamida

Country Status (21)

Country Link
US (2) US8039476B2 (es)
EP (2) EP1918290A1 (es)
JP (1) JP5171831B2 (es)
KR (1) KR101418624B1 (es)
CN (1) CN101622257B (es)
AR (1) AR063231A1 (es)
AU (1) AU2007306319B2 (es)
BR (1) BRPI0717833A2 (es)
CA (1) CA2666653C (es)
CL (1) CL2007002928A1 (es)
DK (1) DK2081935T3 (es)
ES (1) ES2637137T3 (es)
MX (1) MX2009003571A (es)
NO (1) NO342008B1 (es)
PL (1) PL2081935T3 (es)
PT (1) PT2081935T (es)
RU (1) RU2413729C2 (es)
SI (1) SI2081935T1 (es)
TW (1) TWI391392B (es)
UY (1) UY30637A1 (es)
WO (1) WO2008043800A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1921079A1 (en) * 2006-11-08 2008-05-14 Ferrer Internacional, S.A. Amorphous form of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-N-methyl-acetamide
JP5149376B2 (ja) * 2008-03-31 2013-02-20 京セラ株式会社 太陽電池素子及び太陽電池モジュール
IT1391113B1 (it) * 2008-09-30 2011-11-18 Dipharma Francis Srl Procedimento per la preparazione di azelnidipina cristallina

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US399621A (en) * 1889-03-12 Canning-house truck
US6399621B1 (en) * 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
CZ2002783A3 (cs) * 1999-09-02 2004-01-14 Neurocrine Biosciences, Inc. Polymorfy N-methyl-N-[3-[3-(2-Thienylkarbonyl)pyrazol-[1,5-alfa]-pyrimidin-7-yl]fenyl]acetamid a prostředky a způsoby s tím související
DE60309332T2 (de) * 2002-08-26 2007-05-24 Neurocrine Biosciences, Inc., San Diego POLYMORPH VON N-METHYL-N-(3- 3-i2-THIENYLCARBONYLö-PYRAZOL-i1,5-ALPHAö-PYRIMIDIN-7-YL PHENYL)ACETAMID UND ZUSAMMENSETZUNGEN SOWIE VERFAHREN HIERZU
WO2006044903A1 (en) * 2004-10-18 2006-04-27 Neurocrine Biosciences, Inc. HYDRATE OF N-METHYL-N-(3-{3-[2-THIENYLCARBONYL]-PYRAZOL-[1,5-α]- PYRAMIDIN-7-YL}PHENYL)ACETAMIDE AND PROCESSES AND METHODS RELATED THERETO
EP1736475A1 (en) * 2005-06-21 2006-12-27 Ferrer Internacional, S.A. Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates

Also Published As

Publication number Publication date
WO2008043800A1 (en) 2008-04-17
JP5171831B2 (ja) 2013-03-27
ES2637137T3 (es) 2017-10-11
EP2081935B1 (en) 2017-05-24
US8273753B2 (en) 2012-09-25
TWI391392B (zh) 2013-04-01
AR063231A1 (es) 2009-01-14
JP2010505914A (ja) 2010-02-25
US20110224234A1 (en) 2011-09-15
EP2081935A1 (en) 2009-07-29
RU2009117716A (ru) 2010-11-20
BRPI0717833A2 (pt) 2014-06-10
KR101418624B1 (ko) 2014-07-15
RU2413729C2 (ru) 2011-03-10
AU2007306319A1 (en) 2008-04-17
NO20091625L (no) 2009-05-07
SI2081935T1 (sl) 2017-12-29
MX2009003571A (es) 2009-04-14
US20100087451A1 (en) 2010-04-08
KR20090077796A (ko) 2009-07-15
CL2007002928A1 (es) 2008-05-09
CN101622257B (zh) 2013-03-27
TW200827360A (en) 2008-07-01
EP1918290A1 (en) 2008-05-07
AU2007306319B2 (en) 2012-12-06
NO342008B1 (no) 2018-03-12
PT2081935T (pt) 2017-08-29
PL2081935T3 (pl) 2018-04-30
CA2666653C (en) 2014-12-30
CA2666653A1 (en) 2008-04-17
US8039476B2 (en) 2011-10-18
DK2081935T3 (en) 2017-09-04
CN101622257A (zh) 2010-01-06

Similar Documents

Publication Publication Date Title
IL212586A (en) Derivative 3 - (1, 3-benzoxazole-5-yl) pyrzolo [3, 4-d] pyrimidine-4-amine, a pharmaceutical preparation and the use of a drug derivative
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201390913A1 (ru) Новая фармацевтическая композиция
IL201977A (en) 6- (Pyrrolidine-3-Yl) -Pyrazolo [4,3- d] Pyrimidine-4-Ones, Pharmaceuticals Including Them and Their Use in the Preparation of Medicines to Treat Diseases
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
ECSP11011182A (es) Compuestos orgánicos
CL2004001267A1 (es) Compuestos derivados de quinazolina, inhibidor de quinasa; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para preparar un medicamento para tratar trastornos proliferativos celulares tales como ateroesclerosis,
IL201176A (en) 4-amino-1-h-pyrazolo [3,4- d] pyrimidine-3-ram-phenyl, a pharmaceutical containing them and their use in the preparation of a drug
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
CL2007002099A1 (es) Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma.
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
IL184771A (en) Preparations containing amino acids are stored in halogen or in the nitrogen for use.
SV2009002832A (es) 1h imidazopiridinas sustituidas con hidroxi y procedimientos
CL2012001605A1 (es) Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño.
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CL2008003592A1 (es) Compuestos derivados de isoxazolo-pirazina, con afinidad selectiva para el sitio de union al receptor gaba a alfa-5; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trastornos cognitivos, tales como la enfermedad de alzheimer.
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
CL2007003346A1 (es) Compuestos derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome de abstinencia a una sustancia, tras
CO6640216A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
SV2006002384A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
PT1869038E (pt) Compostos de 5,6,7,8-tetra-hidro-imidazo[1,2-a]piridin-2- ilamina substituída e sua utilização para produzir fármacos
AR079136A1 (es) Formas polimorfas de (4,6-diamino-2-(1-(2-fluorobencil)-1h- pirazolo (3,4-b) piridin -3-il)piridin -5-il) carbamato de metilo
UY30637A1 (es) Polimorfo b de n-{2-fluoro-5-[3-(tiofen-2-carbonil)-pirazolo[1,5-a]pirimidin-7-il]-fenil}-n-metil-acetamida
CR9911A (es) Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200618